Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells

作者：Wu, Shenghao^*; Zheng, Cuiping; Chen, Songyan; Lin, Bijing; Chen, Yuemiao; Zhou, Wenjin; Li, Zhenyu

来源：Biochemical and Biophysical Research Communications, 2015, 456(1): 367-372.

DOI：10.1016/j.bbrc.2014.11.089

• Adiponectin
• Adiponectin Receptor
• Chronic myeloid leukemia
• Imatinib
• Resistance
• Bcr-Abl

Adiponectin, a member of adipokines, is a functional ligand for Adiponectin Receptor-1 (AdipoR1) and Adiponectin Receptor-2 (AdipoR2), and has been found to be linked to the risk of CML. Imatinib has undoubtedly revolutionised the management and outcome of chronic myeloid leukemia (CML), however imatinib resistance has been recognized as a major problem in CML therapy. In this study, we first established imatinib-resistant K562 CML cells, and then evaluated the effect of Adiponectin in reversing imatinib resistance. The data presented here demonstrated that Adiponectin was able to reverse 1(562 resistance to imatinib in vitro and in vivo. Additional data with molecular approaches suggested that the reversion of Adiponectin in imatinib resistance signals through AdipoR1 but not AdipoR2 to downregulate Bcr-Abl expression and effect in imatinib-resistant K562 CML cells. Taken together, our data showed that Adiponectin can reverse imatinib resistance in CML, and to a certain extent elucidate the mechanism of Adiponectin reversing imatinib resistance that may provide a new and promising approach in imatinib resistance management in CML therapy.

• 出版日期2015-1-2
• 单位温州市中心医院; 温州医科大学; 徐州医科大学